Industry Solution: Healthcare & Clinical
Explicit Dose Boundaries and Clinical Escalation Paths
Keep dose logic, workflow transitions, and escalation paths readable before clinical handoff absorbs the software context.
The Cost of Legacy Infrastructure
Clinical software and device-workflow teams navigate a landscape where infrastructure brittleness translates directly into market risk.
“Increased risk of dosing errors when the software operates near threshold limits.”
“Failure to escalate critical conditions to human review predictably.”
“Prolonged evaluation cycles and difficulty achieving IEC 62304 review compliance.”
Bounded Dose Logic for Patient Care
BRIK64 helps clinical software and device-workflow teams make selected dose logic, state transitions, and escalation rules explicit. Evaluators can inspect bounded engineering evidence while clinical efficacy, patient safety, and regulatory conclusions remain outside the product claim.
Deterministic Infrastructure
Keep clinical logic inspectable. Bound dose and workflow states, verify escalation conditions explicitly, and emit review-ready engineering state.
Dose and State Bounding
Declare explicitly what the software may recommend or transition between based on patient parameters.
Creates bounded clinical logic that exposes threshold assumptions for engineering review.
Escalation Encoding
Make the review gate explicit so out-of-range states route directly to human escalation.
Makes out-of-range and escalation behavior traceable instead of hidden inside workflow code.
Engineering Review Emission
Return structured output allowing an engineer to trace exactly what recommendation the software produced.
Provides a reviewable software dossier to accelerate clinical safety checks.
Quantifiable Proof
Moving infrastructure from the realm of probability to the precision of mathematics.
Compliance Readiness
Bounded architectural patterns for engineering and compliance review posture.
Trust Markers
Review High-Integrity Software Workflows
For organizations that need bounded architecture review, private registry planning, and explicit evidence posture before production integration.